Alendronate in Primary Hyperparathyroidism: A Double-Blind, Randomized, Placebo-Controlled Trial

Primary hyperparathyroidism (PHPT) is often associated with reduced bone mineral density (BMD). A randomized, double-blind, placebo-controlled trial was conducted to determine whether alendronate (ALN), 10 mg daily, maintains or improves BMD in patients with PHPT. Eligible patients had asymptomatic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The journal of clinical endocrinology and metabolism 2004-07, Vol.89 (7), p.3319-3325
Hauptverfasser: Khan, Aliya A., Bilezikian, John P., Kung, Annie W. C., Ahmed, Mustafa M., Dubois, Sacha J., Ho, Andrew Y. Y., Schussheim, Debra, Rubin, Mishaela R., Shaikh, Atif M., Silverberg, Shonni J., Standish, Timothy I., Syed, Zareen, Syed, Zeba A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!